High-performance liquid chromatography of etoposide in plasma and urineHARVEY, V. J; JOEL, S. P; JOHNSTON, A et al.Journal of chromatography. 1985, Vol 339, Num 2, pp 419-423, issn 0021-9673Article

Etoposide et risque leucémogène = Etoposide leukemogenicityGUENFOUDI-ROULLAUD, M. P; MENAT, C; GIRARD, F et al.Journal de pharmacie clinique (Paris). 1998, Vol 17, Num 2, pp 71-73, issn 0291-1981Article

Etoposide for the treatment of paediatric tumours : What is the best way to give it ?LOWIS, S. P; NEWELL, D. R.European journal of cancer (1990). 1996, Vol 32, Num 13, pp 2291-2297, issn 0959-8049Article

Précision des préparations à base de cytostatiques : étude réalisée sur 3 unités centralisées de reconstitution = Precision of the cytotoxics preparations : study realized on 3 cytotoxics drug preparation unitGIRARD, F; MENAT, C; GUENFOUDI, M.-P et al.Journal de pharmacie clinique (Paris). 1999, Vol 18, Num 1, pp 62-63, issn 0291-1981Conference Paper

Low-dose oral etoposide monotherapy in adult Langerhans cell histiocytosisHELMBOLD, P; HEGEMANN, B; HOLZHAUSEN, H.-J et al.Archives of dermatology (1960). 1998, Vol 134, Num 10, pp 1275-1278, issn 0003-987XArticle

Aryltetralin lignans from Podophyllum hexandrum and Podophyllum peltatumJACKSON, D. E; DEWICK, P. M.Phytochemistry. 1984, Vol 23, Num 5, pp 1147-1152, issn 0031-9422Article

CYTOTOXIC AGENTS OF THUJOPSIS DOLABRATA (L. FIL.) SIEB. ET ZUCC1972; CHEM. PHARM. BULL.; JAP.; DA. 1972; VOL. 20; NO 6; PP. 1150-1155; BIBL. 12REF.Serial Issue

INTERNATIONAL SYMPOSIUM ON THE PODOPHYLLOTOXINS IN CANCER THERAPY, SOUTHAMPTON, ENGLAND, JULY 8-9, 1981CARTER SK ED; MATHE G ED; MCELWAIN T ED et al.1982; CANCER CHEMOTHER. PHARMACOL.; ISSN 0344-5704; DEU; DA. 1982; VOL. 7; NO 2-3; 163 P.; BIBL. DISSEM.Conference Paper

Etudes de la toxicité du VP 16-213. V: Toxicité de 3 mois par voie intraveineuse chez le ratTAKAHASHI, N; KADOTA, T; KAI, S et al.Journal of toxicological sciences. 1986, Vol 11, pp 123-161, issn 0388-1350, supplArticle

EtoposideLa Revue Prescrire. 1996, Vol 16, Num 161, pp 282-284, issn 0247-7750Article

Etudes de la toxicité du VP 16-213. VI: Antigénicité chez le cobayeTAKAHASHI, N; KAWANO, S; KOHMURA, H et al.Journal of toxicological sciences. 1986, Vol 11, pp 163-176, issn 0388-1350, supplArticle

Chromosomal aberrations induced by 5-azacytidine combined with VP-16 (etoposide) in CHO-K1 and XRS-5 cell linesGUIMARAES, A. P. A; DIAS, F. L; CARDOSO, R. S et al.Teratogenesis, carcinogenesis, and mutagenesis. 2003, pp 171-186, issn 0270-3211, 16 p., SUP1Article

A randomized trial of treatment for multisystem Langerhans' cell histiocytosisGADNER, Helmut; GROIS, Nicole; PRITCHARD, Jon et al.The Journal of pediatrics. 2001, Vol 138, Num 5, pp 728-734, issn 0022-3476Article

Chromosome aberrations after etoposide containing cisplatin-based chemotherapy for malignant germ-cell tumoursHERNANDEZ, A. M; FOSSA, S. D; BRØGGER, A et al.Annals of oncology. 2000, Vol 11, Num 7, pp 897-898, issn 0923-7534Article

Developmental toxicity of the topoisomerase inhibitor, etoposide, in rabbits after intravenous administrationNAGAO, T; YOSHIMURA, S; SAITO, Y et al.Teratogenesis, carcinogenesis, and mutagenesis. 1999, Vol 19, Num 3, pp 233-241, issn 0270-3211Article

Lignans from the seeds of Hernandia sonoraUDINO, L; ABAUL, J; BOURGEOIS, P et al.Planta medica. 1999, Vol 65, Num 3, pp 279-281, issn 0032-0943Article

Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxinsSMITH, M. A; RUBINSTEIN, L; MISER, J et al.Journal of clinical oncology. 1999, Vol 17, Num 2, pp 569-577, issn 0732-183XArticle

The mechanism of photo-ionization of podophyllotoxin and its derivatives : a laser flash photolysis studyWANG, S.-L; YAO, S.-D; WANG MEI et al.Radiation physics and chemistry (1993). 1998, Vol 53, Num 6, pp 623-628, issn 0969-806XArticle

A novel enzymatic dehydrogenation of podophyllotoxin congeners by yeast cellsKAMAL, A; DAMAYANTHI, Y.Bioorganic & medicinal chemistry letters (Print). 1997, Vol 7, Num 6, pp 657-662, issn 0960-894XArticle

Cyclosporin A as a multidrug-resistant modulator in patients with renal cell carcinoma treated with teniposideTOFFOLI, G; SORIO, R; GIGANTE, M et al.British journal of cancer. 1997, Vol 75, Num 5, pp 715-721, issn 0007-0920Article

Phamacokinetic evaluation of high-dose etoposide phosphate after a 2-hour infusion in patients with solid tumorsKREIS, W; BUDMAN, D. R; VINCIGUERRA, V et al.Cancer chemotherapy and pharmacology. 1996, Vol 38, Num 4, pp 378-384, issn 0344-5704Article

Preparation of glucosidic derivatives of steganolHICKS, R. P; SNEDEN, A. T.Journal of natural products (Print). 1985, Vol 48, Num 3, pp 357-362, issn 0163-3864Article

PAP modulations in Daudi cells and Molt-3 cells treated with etoposide are mutually associated with morphological evidence of apoptosisTHOMADAKI, E; HAVREDAKI, M; TSIAPALIS, C. M et al.The International journal of biological markers. 2004, Vol 19, Num 3, pp 203-212, issn 0393-6155, 10 p.Article

Etoposide: Discovery and medicinal chemistryMERESSE, Philippe; DECHAUX, Elsa; MONNERET, Claude et al.Current medicinal chemistry. 2004, Vol 11, Num 18, pp 2443-2466, issn 0929-8673, 24 p.Article

Podophyllotoxin: distribution, sources, applications and new cytotoxic derivativesGORDALIZA, M; GARCIA, P. A; DEL CORRAL, J. M et al.Toxicon (Oxford). 2004, Vol 44, Num 4, pp 441-459, issn 0041-0101, 19 p.Article